Atrial fibrillation in Middle Eastern Arabs and South Asians: a scoping review

Amar M Salam1,2,3,*, Rasha Kaddoura4, Vehid Salih5, Sanjay Asopa6

1 College of Medicine, QU Health, Qatar University, 2713 Doha, Qatar
2 Adult Cardiology, Hamad Medical Corporation, 3050 Doha, Qatar
3 Department of Medicine, Weill Cornell Medical College, NY 10031, USA
4 Pharmacy Department, Heart Hospital, Hamad Medical Corporation, 3050 Doha, Qatar
5 Peninsula School of Dentistry, University of Plymouth, PL4 8AA Plymouth, UK
6 South West Cardiothoracic Centre, University Hospitals Plymouth, PL6 8DH Plymouth, UK
*Correspondence: dramarsalam@yahoo.com; Amar.Salam@qu.edu.qa; amss2046@qatar-med.cornell.edu (Amar M Salam)

DOI:10.31083/j.rcm2204127

Most of the published literature on Atrial fibrillation (AF) originates from the northern hemisphere and mainly involves Caucasian patients, with limited studies in certain ethnicities and races. This scoping review was conducted to collect and summarize the pertinent evidence from the published scientific literature on AF in South Asians and Middle Eastern Arabs. MEDLINE, Embase and CENTRAL databases were included in our search. After screening 8995 records, 55 studies were selected; 42 from the Middle East and 13 from South Asia. Characteristics of the included studies were tabulated, and their data were summarized for study design, setting, enrolment period, sample size, demographics, prevalence or incidence of AF, co-morbidities, risk factors, AF types and symptoms, management, outcomes, and risk determinants. Identified literature gaps included a paucity of community or population-based studies that are representative of these two ethnicities/races. In addition, studies that addressed ethnic/racial inequality and access to treatment were lacking. Our study underscores the urgent need to study cardiovascular disorders, particularly AF, in South Asians and Middle Eastern Arabs as well as in other less represented ethnicities and races.

Keywords
Arabs, Atrial fibrillation, Middle East, Scoping review, South Asians

1. Introduction
There has been an increasing interest in the impact of ethnicity and race on cardiovascular disorders. Patients from the same race and/or ethnicity share common genetics as well as environmental exposures. This may be responsible for the differences observed between different races/ethnicities in the incidence, presentation and outcomes of cardiovascular disorders as well as for the differences in response to therapy [1]. In addition, racial and ethnic inequalities and bias may also play an important role. Variations in access to care, economic status and education have all been linked to race/ethnicity and can affect awareness of the disease, which may lead to underdiagnosis and insufficient treatment.

Atrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice, accounting for approximately one-third of hospitalizations for cardiac rhythm disturbances [2]. Most of the published literature on AF originates from North America and Europe involving mainly Caucasian patients [3]. Other ethnicities are largely under-represented particularly South Asians and Middle Eastern Arabs. Therefore, our aim was to perform a scoping review to identify and summarize the current evidence on AF in these two ethnicities with the overarching objective to identify research gaps and inform future research in this area.

2. Methods
A Scoping review is a systematic method of knowledge synthesis that examines and maps evidence on a specific subject matter, thus, identifying key concepts, theories, sources of evidence, and research [4]. This scoping review follows the five steps proposed by Arksey and O’Malley [5]: (1) identifying the research question, (2) identifying relevant studies, (3) selecting studies, (4) collecting data, and (5) mapping, summarizing and describing the results.

2.1 Eligibility criteria
Studies that reported various aspects of AF including epidemiology, co-morbidities, risk factors, management and/or clinical outcomes in the Middle East or South Asia were included. Exclusion criteria included studies on sub-clinical AF, post-operative AF, genetics, cost-effectiveness, and smart devices. The countries in this review were categorized according to the world regions as per the World Health Organization (WHO), i.e., South-East Asia and Eastern Mediterranean regions [6]. For the purpose of this review, the terms Middle East(ern) and South Asia(n) will be used.
2.2 Search strategy

A comprehensive electronic literature search using MEDLINE, EMBASE, and CENTRAL was performed on September 26, 2020. Boolean terms (“OR” and “AND”), Medical Subject Headings (MeSH), Emtree and broad keywords were used. The search terms were combined and included: “atrial fibrillation”, “Middle East”, “South Asia”, “Arab”, individual country and nationality. Search limitations were not applied. Reviews and meta-analyses, international registries and the references’ lists of the retrieved articles were manually screened to identify additional relevant studies. The detailed search strategy is described in Supplementary Table 1.

2.3 Study selection and data extraction

All records (N = 8995) were reviewed on the titles and abstracts levels. Duplicate publications, posters, abstracts, irrelevant studies or those that did not meet the inclusion criteria were excluded. Relevant abstracts (n = 305) were screened and 84 of them were retrieved in full texts. After excluding 29 studies (Supplementary Table 2), the search strategy resulted in 55 studies [7–61] (Figs. 1,2). However, 17 studies [45–61] were related to three registries [30, 33, 41] (Supplementary Table 3) and were used when provided additional data or analysis. The included studies were tabulated, and their data were extracted for the study design, setting, enrolment period, sample size, demographics, prevalence or incidence of AF, co-morbidities, risk factors, AF types and symptoms, management, outcomes, and risk determinants (Supplementary Tables 3,4,5,6,7).

3. Results

The selected articles were categorized based on the region, i.e., Middle East (n = 42) and South Asia (n = 13) (Tables 1,2, Ref [12, 15, 20, 22, 36, 38, 39] and Supplementary Table 3). Studies from the Middle East included 15 single-center [7–21] and four multi-center [22–25] studies, five non-AF registries [26–30] with seven related publications [45–51], and three AF registries [31–33] with eight related publications [52–59]. Studies from South Asia included three single-center [34–36] and two multi-center [37, 38] studies, one non-AF [39] and five AF [40–44] registries. Two additional publications [60,61] came out from the COOL-AF registry [41]. By disregarding the 17 registry-related articles that were mentioned above [45–61], the studies were performed in the following countries: India (n = 6), Kingdom of Saudi Arabia (KSA) (n = 7), Pakistan (n = 4), Thailand (n = 4), Iran (n = 4), Qatar (n = 2), combined six adjacent Middle Eastern countries (n = 2), and one study in each of the following: Bahrain, Egypt, Iraq, Jordan, Kuwait, Morocco, Nepal, Tunisia, and United Arab Emirates (UAЕ). With the exception of two papers [14, 32], the studies enrolled patients from the hospital settings, between 1989 and 2019. In the single- and multi-center studies, sample size, age range and female distribution of AF patients in the Middle Eastern and South Asian regions were 3514 and 9899 patients, 58.8–68.4 and 51.2–64.6 years, and 36.0–65.0% and 48.8–58.1%, respectively. The respective data from AF registries were 3181 and 9974 patients, 56.0–61.7 and 54.7–67.4 years, and 40.5–48.5% and 40.1–51.5%, respectively. Comparable age ranges and female proportions were seen in the studies (n = 7) and registries analyses (n = 5) that investigated AF in specified patient populations such as acute coronary syndrome (ACS) [15, 18, 27], acute [36] and chronic heart failure [29], hypertension [38], and haemodialysis (HD) [22]. However, in two [20, 36] out of four studies [12, 20, 28, 36] that enrolled patients with stroke, patients were older (71 years), while patients with rheumatic heart disease (RHD) were younger (40.2 years) and with higher female proportion (72.3%) [39].

| Characteristic | ME region | SA region | Total |
|---------------|-----------|-----------|-------|
| Study design  |           |           |       |
| Cohort        | 4         | 1         | 5     |
| Case–control  | 1         | -         | 1     |
| Cross-sectional | 9         | 2         | 11    |
| Retrospective | 5         | 2         | 7     |
| Registries*   |           |           |       |
| AF registry   | 11        | 7         | 18    |
| Non-AF registry | 12        | 1         | 13    |
| Study Setting |           |           |       |
| Community/Primary care | 1 | - | 1 |
| Hospital patients/no population denominator | 26 | 9 | 35 |
| Hospital patients/population denominator | 14 | 4 | 18 |
| Hospital patients and community | 1 | - | 1 |
| Year of final data collection |           |           |       |
| 2005 and before | 5 | 1 | 6 |
| 2006–2015    | 28        | 5         | 33    |
| 2016 onwards | 9         | 7         | 16    |
| Publication date |           |           |       |
| Before 2012  | 9         | -         | 9     |
| 2012 onwards | 33        | 13        | 46    |

*Numbers of studies included the additional publications (n = 17) related to the included registries.

Abbreviations: AF, atrial fibrillation; ME, Middle Eastern; SA, South Asian.

3.1 Incidence and prevalence of AF

The incidence and prevalence of AF was reported in association with other diseases. The overall incidence of AF during hospitalization was 1.8% in patients admitted with acute myocardial infarction (AMI) in Qatar [48], with the incidence in Arabs being higher than that in South Asians (3.1% vs. 0.8%). From the earlier data of the same Qatari registry (1991 to 2002) [45], the overall annual incidence among Qatari was higher than that of other nationalities (12% vs. 8.0%). However, the rate (8.0–9.3%) remained consistent over years for the overall patient population, i.e., those hospitalized with acute cardiac illness [30, 46, 47, 50]. The incidence of AF in the Gulf RACE-2 registry was 2.7% among patients hospitalized with ACS [27]. Two studies from Pak-
Fig. 1. Flowchart of search strategy and identification of relevant studies with summary of the inclusion and exclusion process.

istan [15, 18] reported similar frequency (9.1%) in patients hospitalized with AMI. The prevalence of AF among general hospital admissions was 3.4% in Bahrain [13], 4.2% in Kuwait [19], and 5.8% in Pakistan [24]. Whereas, a lower prevalence (2.8%) was reported in the only study that was conducted in a primary health care center in Iran [14]. The prevalence of AF was 7.8% among patients on maintenance HD in Jordan [22], and 10.6% in patients with chronic heart failure in Morocco [29]. In Iran, the prevalence of AF among patients with stroke was 11.1% [20], while in Qatar, it was 6.4%. In the latter Qatari study, 2.6% of stroke patients were newly diagnosed with AF [28]. The highest AF prevalence reported was 17.8% in patients hospitalized with heart failure [26], and 23.9% in patients with RHD [39] (Table 2 and Supplementary Table 3).

3.2 Characteristics of AF patients

3.2.1 Co-morbidities and risk factors

The most common co-morbidities associated with AF were hypertension, diabetes mellitus, heart failure and stroke which were comparable between the Middle Eastern and the South Asian registries (hypertension 52.0–63.0% and 31.4–68.5%, diabetes mellitus 30.0–48.0% and 16.1–36.2%, heart failure 27.0–31.7% and 15.5–27.2%, stroke 9.0–13.0% and 9.1–17.8%, respectively). Analyses from the Gulf SAFE registry [33] showed similar frequencies of the first three aforementioned co-morbidities in patients with stroke [57], and similar frequencies of hypertension and heart failure in patients with diabetes mellitus [54]. In non-AF registries (stroke and heart failure), AF patients with stroke [28] and acute heart failure [26] had higher frequencies of both hypertension (72.3% and 70.8%) and diabetes (67.7%, including pre-diabetics, and 55.9%), than that for AF patients with chronic heart failure (55.0% and 65.9%) [29] and ACS (39.0% and 44.2%) [27], respectively. Valvular heart diseases were more prominent in South Asia (40.7–50.3% versus 8.0–24.0%) than in the Middle East. In the non-registry studies, there were noticeable variations in the reported frequencies of co-morbidities accompanied with variations in the terms of definitions used for the associated conditions. The mean HAS-BLED score ranged between 1.1 and 1.9 across the included studies, while mean CH_fADS_VASc score between 2.3 and 4.1, and CHADS_s score between 1.6 and 2.3, with the majority of patients having high stroke risk, i.e., CHADS_s ≥2 in 36.7 to 71.0% of patients (Table 3, Ref [12, 15, 20, 22, 33–38, 42–44, 55] and Supplementary Table 4).

3.2.2 Types and symptoms of AF

There were few studies that reported the types and symptoms of AF. The frequency of new onset AF was reported in two Middle Eastern studies as 27.0% [24] and 59.0% [13], which was higher than that reported in the AF registries
The selected studies. Visual summary of the studies: AF or non-AF registry (Top) and single- or multi-center non-registry (Bottom) studies. The studies enrolled either AF patients only or specified subgroups which included proportion of patients with AF. The studies which are represented in an oval shape have an enrollment period of two years or less. Abbreviations/acronyms: AF, atrial fibrillation; COOL-AF, Cohort of Antithrombotic Use and Optimal INR Level in Patients With Non-Valvular Atrial Fibrillation in Thailand; GARFIELD-AF, Global Anticoagulant Registry in the FIELD-Atrial Fibrillation; Gulf RACE-2, second Gulf Registry of Acute Coronary Events; Gulf SAFE, Gulf Survey of Atrial Fibrillation Events; HEARTS, Hearts Function Assessment Registry Trial in Saudi Arabia, HP-RF/RHD, Himachal Pradesh- Rheumatic Fever/Rheumatic Heart Disease; IHRS-AF, Indian Heart Rhythm Society-Atrial Fibrillation; IRAF, Iranian registry of atrial fibrillation; RealiseAF, Real Life global Survey Evaluating patients with atrial fibrillation; SAS, Saudi Atrial Fibrillation Survey.

The proportion of patients with permanent AF was higher in AF registry studies as compared with that in non-AF registry studies. The proportion of patients with persistent AF was higher in the latter studies. The most common symptoms at presentation, i.e., palpitation and dyspnea, were reported in more than half of the patients across the studies (Table 4, Ref[12, 13, 15, 20, 22, 24, 32, 34, 36, 38, 42], and Supplementary Table 5). A single-centre study from Nepal [35] reported AF types and symptoms in patients with valvular and non-valvular AF. Paroxysmal AF was more common in non-valvular AF (55.2% versus 7.8%), while permanent AF was more common in valvular AF (51.0% versus 10.4%). Symptoms did not differ between the two groups (Supplementary Table 5).

3.3 Management of AF

Rate control was the strategy reported in more than half of the patients. Rhythm control was approached in up to one-third of the patients using amiodarone in up to 40% of them. Beta-blockers were used in more than 50% of the patients, digoxin in 30% and calcium channel blockers in approximately 20% of them. Only two AF registries [31, 32] reported the use of ablation. In the Saudi registry (SAS), 3.8% of patients had been ablated [32]. The Iranian registry (IRAF) reported ablation use in 34.0% and 29.8% of patients with familial and non-familial AF, respectively [31]. The use of vitamin K antagonists (VKAs) across the studies ranged from about 40% to 70%, and more than 90% in two studies [34, 41]. Of the 14 studies [17, 20, 24, 26, 31, 32, 34, 35, 40, 41, 43, 44, 46, 59] that reported anticoagulation agents use, seven studies [20, 31, 35, 40, 41, 43, 44] recruited patients in the non-vitamin K oral anticoagulants (NOACs) era, i.e., beyond 2010. Of the seven studies, two did not report NOACs use [20, 35], four South Asian AF registries [40, 41, 43, 44] reported use between 1.9% to 9.1%, and the IRAF registry reported higher average NOACs than VKAs use (45.7% versus 23.0%) [31]. Across the AF registries, aspirin and clopidogrel use ranged from 19.5% to 54.4% and 11.0% to 19.5%, respectively (Table 5, Ref[32, 55, 59] and Supplementary Table 6).

3.4 Outcomes in AF

The main adverse outcomes reported by the studies included mortality (in-hospital, one-year), cerebrovascular events, and bleeding. In-hospital mortality was reported in 0.79% of patients in Bahrain [13] and was doubled in Thailand (1.6%) [37]. The rate was 3.6% in Qatar among patients admitted with general cardiac conditions [30], with a rate of 4.8% in Middle Eastern and 1.2% in South Asian patients as defined in the study [47]. The rates were higher in
patients with acute heart failure (6.7%) [26], chronic kidney disease (CKD) (11.7%) [51], ACS (14.7%) [27], and acute ischemic stroke (9.0% [20] and 26.8% [36]). One-year mortality rate ranged from 6.5% to 18.1% in four South Asian studies [37, 40, 44, 44]. Gulf SAFE registry reported a rate of 15.0% [58] with a significantly lower mortality rate in patients who were compliant with the AF Better Care (ABC) pathway (7.3% versus 13.1%, \( p = 0.033 \)) [55]. In the same registry, diabetic patients had significantly higher one-year mortality rate than non-diabetics (14.4% versus 9.6%, \( p = 0.003 \)) [53]. Similarly, diabetic patients who were compliant with the ABC pathway had lower mortality rate as well (5.8% versus 15.9, \( p = 0.0014 \)) [54]. Higher one-year mortality rates (\( >20\% \)) were reported in AF patients presenting with ACS [27] or acute heart failure [26]. The observed rate of cerebrovascular accident (CVA) and/or transient ischemic attack (TIA) in the South Asian AF registries ranged from 0.85% to 3.0% [43, 44, 60], while a single-centre study found much higher rates; 17.2% in non-valvular and 23.1% in valvular AF patients [35]. The Gulf SAFE reported a rate of 6.4% [58], while the Qatari registry reported a lower rate of 1.1% in patients admitted with cardiac condition [46]. Additionally, the rate was higher in Middle Eastern (1.4%) than South Asian (0.6%) population in the Qatar registry [47]. The rates of CVA/TIA in special AF patient populations were 2.3%, 2.0%, 1.8–2.8%, and 6.7% in CKD [51], acute heart failure, [26] AMI/ACS [27, 48], and RHD [39], respectively. Two single-center studies from Iran reported higher rates in patients presenting with AMI (12.5% [18] and 13.6% [15]). Finally, the rate of major bleeding in studies from the Middle East [26, 27, 58] ranged from 1.1% to 1.7% including those in patients presenting with ACS [27] and acute heart failure [26]. However, one-single center study from KSA reported a rate of 35.6% in those with high risk of bleeding [7].

### Table 2. Characteristics of studies on AF.

| Morbidity/Risk                  | Single- and multi-center studies* | Non- AF registries | AF registries |
|---------------------------------|-----------------------------------|--------------------|---------------|
|                                | ME region | SA region | ME region | SA region | ME region | SA region |
|---------------------------------|-----------|-----------|-----------|-----------|-----------|-----------|
| Heart failure                   | 14.0–45.6%| 12.3–56.5%| 27.0–31.7%| 15.5–27.2%|           |           |
| Hypertension                    | 23.7–79.5%| 10.2–30.5%| 52.0–63.0%| 31.4–68.5%|           |           |
| Diabetes mellitus               | 12.0–68.3%| 5.0–15.0%  | 30.0–48.0%| 16.1–36.2%|           |           |
| Prior stroke                    | 11.7–23.0%| 0.6% [37]  | 9.0–13.0% | 9.1–17.8% |           |           |
| CAD/IHD                         | 3.5–55.8% | 13.6% [35]| 28.0–28.5%| 5.4–34.8% |           |           |
| Valvular heart disease          | 23.6–58.7%| 5.1–14.9% | 8.0–24.0% | 40.7–50.3%|           |           |
| Chronic kidney disease          | 18.9–36.8%| 1.3–1.8%  | 27.5% [35]|           |           | 4.5–10.3% |
| Smoking                         | 22.7–42.0%| -         | 23.0% [55]| 16.0–18.6%|           |           |
| HAS-BLED score (mean)           | 1.2–1.9   | -         | 1.1% [33] | 1.5–1.6   |           |           |
| CHADS2 score (mean)             | 2.6–4.1   | 1.8 [37]  | 2.3% [33]| 2.9–3.0   |           |           |
| CHADS2 score = 0                | 2.0–2.3   | -         | 1.6% [33]| 1.8 [41]  |           |           |
| CHADS2 score ≥1                 | 5.0%      | -         | 28.5% [33]| 11.6–27.2%|           |           |
| CHADS2 score ≥2                 | 24.0–26.0%| -         | 27.5% [33]| 19.9–36.2%|           |           |
|                                 | 69.0–71.0%| -         | 44.0% [33]| 36.7–68.5%|           |           |

* Data from studies that investigated AF in specified patient populations (e.g., stroke) are not included in this table unless stated [12, 15, 20, 22, 36, 38].

** In hypertensive patients [38].

Abbreviations: AF, atrial fibrillation; ME, Middle Eastern; SA, South Asian.

### Table 3. Co-morbidities and risk factors in AF patients.

| Morbidity/Risk                  | Single- and multi-center studies* | AF registries |
|---------------------------------|-----------------------------------|---------------|
|                                | ME region | SA region | ME region | SA region |
| Heart failure                   | 14.0–45.6%| 12.3–56.5%| 27.0–31.7%| 15.5–27.2%|           |           |
| Hypertension                    | 23.7–79.5%| 10.2–30.5%| 52.0–63.0%| 31.4–68.5%|           |           |
| Diabetes mellitus               | 12.0–68.3%| 5.0–15.0%  | 30.0–48.0%| 16.1–36.2%|           |           |
| Prior stroke                    | 11.7–23.0%| 0.6% [37]  | 9.0–13.0% | 9.1–17.8% |           |           |
| CAD/IHD                         | 3.5–55.8% | 13.6% [35]| 28.0–28.5%| 5.4–34.8% |           |           |
| Valvular heart disease          | 23.6–58.7%| 5.1–14.9% | 8.0–24.0% | 40.7–50.3%|           |           |
| Chronic kidney disease          | 18.9–36.8%| 1.3–1.8%  | 27.5% [35]|           |           | 4.5–10.3% |
| Smoking                         | 22.7–42.0%| -         | 23.0% [55]| 16.0–18.6%|           |           |
| HAS-BLED score (mean)           | 1.2–1.9   | -         | 1.1% [33] | 1.5–1.6   |           |           |
| CHADS2 score (mean)             | 2.6–4.1   | 1.8 [37]  | 2.3% [33]| 2.9–3.0   |           |           |
| CHADS2 score = 0                | 2.0–2.3   | -         | 1.6% [33]| 1.8 [41]  |           |           |
| CHADS2 score ≥1                 | 5.0%      | -         | 28.5% [33]| 11.6–27.2%|           |           |
| CHADS2 score ≥2                 | 24.0–26.0%| -         | 27.5% [33]| 19.9–36.2%|           |           |
|                                 | 69.0–71.0%| -         | 44.0% [33]| 36.7–68.5%|           |           |

* Data from studies that investigated AF in specified patient populations (e.g., stroke) are not included in this table unless stated [12, 15, 20, 22, 36, 38].

Abbreviations: AF, atrial fibrillation; CAD, coronary heart disease; IHD, ischemic heart disease; ME, Middle Eastern; SA, South Asian.
from South Asia reported rates ranged from 0.31% to 4.4% [35, 43, 44, 60]. A study from UAE found that the use of inappropriate NOACs doses subjected the patients to higher ischemic stroke and major bleeding rates compared to those on appropriate doses (9.9% versus 3.1%, \( p < 0.01 \) and 11.7% versus 6.0%, \( p = 0.04 \); respectively) [8] (Supplementary Table 7).

### 3.5 Risk determinants of AF

In hypertensive Thai patients, older age, male gender, and presence of CKD increased the prevalence of AF. On a multivariate analysis, factors of strongest association with increased prevalence were age of 65 years or above (adjusted odd ratio (adj OR) 2.86, 95% confidence interval (CI), 1.89–4.33; \( p < 0.001 \)) followed by male gender (adj OR, 1.98, 95% CI, 1.35–2.91; \( p < 0.01 \)), lower low-density lipoprotein-cholesterol (adj OR, 1.87, 95% CI, 1.28–2.73; \( p < 0.01 \)) and high uric acid levels (adj OR, 1.48, 95% CI, 1.02–2.17; \( p < 0.05 \)). The presence of combined factors, further increased the risk. Odds increased to 2.46 (95% CI, 1.66–3.63; \( p < 0.001 \)) when two risk factors were present and to 8.99 (95% CI, 5.02–16.07; \( p < 0.001 \)) when four factors were combined [38]. In Indian patients with RHD, the following variables were independent determinants of AF, age (adj OR, 1.04, 95% CI, 1.03–1.06), mitral stenosis (MS) (moderate MS (adj OR, 2.4, 95% CI, 1.7–3.4) or severe MS (adj OR, 2.1, 95% CI, 1.5–3.0)), left atrial size (adj OR, 1.10, 95% CI, 1.08–1.11), New York Heart Association classes (II, III, IV), all degrees of tricuspid regurgitation (TR), and combined mitral regurgitation and MS with or without TR [39]. In patients hospitalized with AMI, the only independent factor of AF was age (adj OR, 1.06, 95% CI, 1.04–1.08; \( p = 0.001 \)) in the Qatari registry [48].

### 3.6 Risk determinants of outcomes in AF

In the Qatari registry, ACS was associated with increased risk of in-hospital mortality (adj OR, 4.36, 95% CI, 1.77–10.74; \( p = 0.001 \)) [30, 47] and not the age alone as a correlate with mortality. In a multiple logistic regression analysis, beta-blocker administration upon hospital admission was a good correlate with reduced in-hospital mortality (adj OR, 0.36, 95% CI, 0.15–0.87; \( p = 0.02 \)) [30]. Gender [46] or ethnicity [47] were not associated with poor outcomes. A multivariate analysis found the following as correlates with in-hospital mortality, cardiogenic shock (adj OR, 285, 95% CI, 84.0–970; \( p = 0.001 \)), diabetes mellitus (adj OR, 1.52, 95% CI, 1.03–2.26; \( p = 0.04 \)), and chronic renal impairment (adj OR, 1.18–3.68; \( p = 0.001 \)) [46]. In Thailand, correlates with mortality after AF hospitalization included CKD (hazard ratio (HR), 2.01, 95% CI, 1.68–2.41; \( p < 0.0001 \)), high CHA\(_2\)DS\(_2\)-VASc score (e.g., ≥6; HR, 2.23, 95% CI, 1.34–3.70; \( p < 0.002 \)), and RHD (HR, 1.72, 95% CI, 1.53–1.92; \( p < 0.0001 \)) [37]. In Thai patients who experienced AF-associated acute ischemic stroke on admission or during hospitalization, age (>75 year) and acute kidney injury were independent risk factors for three-month mortality (adj OR, 3.08, 95% CI, 1.17–8.13; \( p = 0.019 \) and adj OR, 6.38, 95% CI, 1.96–20.76; \( p = 0.001 \) respectively). Baseline oral anticoagulation therapy was associated with 87% risk reduction (adj OR, 0.13, 95% CI, 0.03–0.64; \( p = 0.002 \)) [36].

In the Gulf SAFE registry, in-hospital or emergency room (ER) mortality was strongly associated with congestive heart failure (adj OR, 2.64, 95% CI, 1.79–3.89; \( p < 0.001 \)), peripheral vascular disease (adj OR, 2.26, 95% CI, 1.01–5.08; \( p = 0.048 \)), and reason for ER visit (cardiac and noncardiac). Warfarin and antiplatelet use upon discharge were independent protective factors (adj OR, 0.51, 95% CI, 0.32–0.83; \( p = 0.006 \) and adj OR, 0.55, 95% CI, 0.35–0.87; \( p = 0.01 \), respectively) [59]. When comparing patients with and without diabetes mellitus, in-hospital or ER mortality was associated with only the presence of CKD (relative risk (RR) 6.38, 95% CI 2.73–14.87) in diabetic patients. Whereas, in
Table 5. Management in AF patients.

| Medication/strategy | ME region Baseline medication [55] | In-hospital [32, 59] | SA region Baseline medication |
|---------------------|------------------------------------|----------------------|-------------------------------|
| **Medication**      |                                    |                      |                               |
| Beta-blocker        | 58.3%                              | 66.0%                | 21.0–38.5%                    |
| Calcium channel blocker | 16.3%                        | 20.8%                | 15.0–24.9%                    |
| Digoxin             | 36.1%                              | 30.3%                | 22.2–31.9%                    |
| Amiodarone          | 9.2%                               | 9.0–42.3%            | 7.4–37.2%                     |
| Other antiarrhythmics | 3.1%                            | 4.0–57.7%            | 0.8–33.0%                     |
| **Antithrombotic agent** |                                |                      |                               |
| Vitamin K antagonists | 51.9%                        | 38.5%                | 40.0–90.0%                    |
| NOACs               | -                                  | -                    | 1.9–9.1%                      |
| Aspirin             | 54.4%                              | 35.5%                | 19.5–23.0%                    |
| Clopidogrel         | 11.0%                              | 1.5%                 | 13.1–19.5%                    |
| **Strategy**        |                                    |                      |                               |
| Rate control        | -                                  | 65.0–66.2%           | 46.1–87.8%                    |
| Rhythm control      | -                                  | 12.0–22.0%           | 12.2–35.2%                    |
| Ablation            | -                                  | 3.8%                 | -                             |

Abbreviations: AF, atrial fibrillation; ME, Middle Eastern; NOACs, non-vitamin K oral anticoagulants; SA, South Asian.

non-diabetics, several factors were involved, age ≥75 years (RR, 3.04, 95% CI, 1.69–5.50), CKD (RR, 7.41, 95% CI, 3.69–14.92), heart failure (RR, 2.05, 95% CI, 1.21–3.68), and stroke (RR, 3.00, 95% CI, 1.51–5.98). Correlates with one-year mortality in both diabetics and non-diabetics, were older age (≥75 year), heart failure, and CKD. Digoxin use increased mortality risk by 74% in the absence of diabetes (RR, 1.74%, 95% CI, 1.04–2.90; p = 0.035). In contrast, 55% mortality risk reduction was associated with beta-blocker use in diabetic patients (RR, 0.45, 95% CI, 0.24–0.84; p = 0.012) [53]. History of previous stroke or TIA increased the risk of one-year stroke event rate (OR, 2.81, 95% CI, 1.82–5.00; p = 0.001). Similarly, antithrombotic therapy (ATT) undertreatment (OR, 2.76, 95% CI, 1.42–5.35; p = 0.003) but not ATT overtreatment, was associated with one-year stroke risk. However, ATT overtreatment was the only factor associated with significantly higher one-year major bleeding event rate (OR, 3.29, 95% CI, 1.51–7.15; p = 0.003) [57]. In patients with non-valvular AF, smoking, cardiac reasons for ER visit, and both CHADS2 and CHA2DS2-VASc scores of ≥2 were independent correlates with one-year stroke or TIA. Warfarin prescription upon discharge reduced the risk by about 60% (OR, 0.38, 95% CI, 0.17–0.83; p = 0.015) [59]. Adherence to the ABC pathway was significantly associated with lower six-month and one-year mortality either in the entire registry population (OR, 0.31, 95% CI, 0.13–0.77; p = 0.013 and OR, 0.46, 95% CI, 0.25–0.86; p = 0.015, respectively) [55], or in diabetic population (OR, 0.18, 95% CI, 0.42–0.75; p = 0.019 and OR, 0.29, 95% CI, 0.11–0.76; p = 0.012, respectively) as compared to the non-ABC adherent group [54].

4. Discussion

The objective of this scoping review was to assess the extent of the available literature of AF in South Asians and Middle Eastern Arabs, then identify and summarize various related aspects such as clinical features and management. A preliminary search of MEDLINE and the Cochrane Database of Systematic Reviews was conducted and no current or undereway systematic reviews or scoping reviews on the topic were identified. The reason we chose a scoping review over a systematic review for this study was the broad research question. While a rigorous and detailed in-depth analysis of data is not normally required in scoping reviews, a systematic inquiry was planned and conducted with the synthesis of available evidence into several themes to comply with the study objectives. The study identified significant research gaps in the reporting of this important arrhythmia in the two specified ethnicities/races.

Previous reports have suggested a lower incidence and prevalence of AF in the individuals of non-European ancestry. Data from the United Kingdom-based West Birmingham Atrial Fibrillation Project [62, 63] suggested a low prevalence of AF (0.6%), in Indo-Asians aged >50 years, compared with 2.4% in the general study population. The incidence of AF in individuals of European ancestry was higher than that in individuals of African, Chinese, or Japanese backgrounds as suggested by analysis of data from the multinational ASSERT trial [64]. We observed considerable variations in the epidemiological data reported in the included studies, with incidence/prevalence rates ranging from 2.8 to 17.8% in the Middle Eastern region and 3.4 to 23.9% in South Asian region.
Table 6. Patient characteristics in international registries.

| Characteristic                  | GARFIELD-AF [70] | GLORIA-AF phase I [69] | GLORIA-AF phase II [68] | RealiseAF [71] | RE-LY AF [67] |
|--------------------------------|------------------|------------------------|-------------------------|----------------|---------------|
| Sample size                    | 39898            | 1063                   | 15092                   | 10523          | 15400         |
| Relevant regions (Countries involved) | Asia (Singapore, China, Japan, South Korea, Thailand and India) | ME (Egypt, Lebanon, Turkey, UAE) | Africa and ME (KSA, Lebanon, South Africa, UAE) | Asia (Azerbaijan, India, Taiwan, Turkey) | ME and Africa (Algeria, Egypt, Lebanon, Morocco, Tunisia) |
| Others (Australia, Egypt, South Africa, UAE) | -                | -                      | -                       | -              | -             |
| **Characteristics per region**  |                  |                        |                         |                |               |
| **Results presentation**        | Asia/Others      | ME                     | Africa-ME               | Asia/Africa-ME | India/ME      |
| **Region size (%)**             | 11117 (27.8%)/1227 (3.0%) | 59 (5.6%)              | 597 (4.0%)              | 1703 (16.1%)/1680 (15.9%) | 2536 (16.4%)/885 (5.7%) |
| **Enrolment period**            | Mar 2010 to Sept 2015 | May 2011 to Jan 2013   | Nov 2011 to Dec 2014    | Oct 2009 to May 2010 | Sept 2008 to April 2011 |
| **Age (year)**                  | 67.4/68.5        | 65.0                   | 70.0                    | 66.4/61.1      | 57.9/58.6     |
| **Female sex (%)**              | 41.0/42.2%       | 57.6%                  | 47.6%                   | 46.0/54.2%     | 50.3/43.6%    |
| **Heart failure**               | 19.8/17.8%       | 57.6%                  | 80.4%                   | 17.7/28.4%     | 41.6/56.1%    |
| **Hypertension**               | 68.4/76.6%       | 79.7%                  | 80.4%                   | 67.5/54.7%     | 20.2/36.2%    |
| **Diabetes mellitus**           | 21.7/23%         | 37.5%                  | 42.2%                   | 24.9/22.7%     | 7.4/22.1%     |
| **Prior stroke**                | 10.8/16.5%       | 10.2%                  | 18.1%                   | -              | -             |
| **CAD/IHD**                     | CAD: 17.5/26.2%  | CAD: 27.4%             | CAD: 32.5%              | CAD: 32.8/19.1% | MI: 15.5/17.2% |
| **VHD**                         | -                | -                      | -                       | -              | -             |
| **RHD**                         | -                | -                      | -                       | -              | -             |
| **Smoking**                     | 12.8/10.4%       | -                      | -                       | -              | -             |
| **HAS-BLED**                    | 1.4/1.6          | -                      | -                       | -              | -             |
| **CH2ADS2-VASc**                | 2.9/3.3          | -                      | -                       | -              | -             |
| **HAS-BLED ≥3**                 | -                | 16.9%                  | 10.2%                   | -              | -             |
| **CHADS2 ≥2**                   | -                | 61.0%                  | -                       | -              | -             |
| **CH2ADS2-VASc ≥2**             | -                | 89.8%                  | 89.8%                   | -              | -             |
| **New onset**                   | -                | -                      | 7.8/10.7%               | -              | -             |
| **Paroxysmal**                  | -                | 67.8%                  | 47.9%                   | 26.1/17.2%     | 20.5/20.8%    |
| **Persistant**                  | -                | 22.0%                  | 31.8%                   | 17.9/21.6%     | 32.9/7.5%     |
| **Permanent**                   | -                | 10.2%                  | 20.3%                   | 48.2/50.5%     | 46.6/71.7%    |
| **Amiodarone**                  | -                | -                      | -                       | -              | -             |
| **Vitamin K antagonists**        | -                | 45.0%                  | 31.8%                   | -              | -             |
| **NOACs**                       | -                | -                      | 55.6%                   | -              | 14.2/33.1%    |
| **Aspirin**                     | -                | 37.5%                  | 9.9%                    | -              | 24.1/38.1%    |
| **Rate control**                | -                | -                      | 60.4/55.4%              | -              | -             |
| **Rhythm control**              | -                | -                      | 23.2/25.7%              | -              | -             |

Abbreviations: ACS, acute coronary syndrome; CAD, coronary artery disease; IHD, ischemic heart disease; KSA, kingdom of Saudi Arabia; ME, Middle East; MI, myocardial infarction; NOACs, non-vitamin K oral anticoagulants; RHD, rheumatic heart disease; UAE, United Arab Emirates; VHD, valvular heart disease.
(Table 2). In addition, in our study, data of AF in these two ethnicities were reported in association with other diseases such as heart failure, ACS and stroke. Furthermore, most of the available data originates from hospital-based studies which may under- or over-estimate the true prevalence of the disease in the community. Moreover, the reported studies focused on data from the urban populations, with under-representation of patients living in remote or rural areas. Such patient populations could have different risk factors for AF and limited access to healthcare compared with their counterparts from the urban populations. Data on the accurate incidence and prevalence of AF in South Asians and Arabs, in longitudinal epidemiological studies that are representative of the two ethnicities are therefore needed.

In our study the age range of AF patients was 58.8–68.4 years in the Middle Eastern region, and 51.2–64.6 years in the South Asian region. Compared with our findings, most of AF patients (>70%) of European ancestry were older, aged more than 65 years [65]. Moreover, the leading prevalent AF-associated co-morbidities in our study included hypertension, diabetes mellitus, heart failure, valvular heart diseases and stroke. This was consistent with studies in other ethnicities from around the world [65]. In one study examining secular trends between the two ethnicities with AF over 20 years (1991–2010), Salam et al. [47] reported significant variations in the prevalence of underlying cardiac aetiologies in both ethnicities. There was an increase in the prevalence of ischemic heart disease and a decrease in that of valvular heart disease in the latter years of the study. In addition, there was an increase in the prevalence of diabetes mellitus and hypertension in both groups. Consistent with our findings, valvular heart disease used to be a major cause of AF in the Western world [66], but because of the wide availability of early treatments for rheumatic fever and streptococcal infection these diseases are now rare in the developed world.

5. International registries

Middle Eastern Arabs and South Asians were included as part of five AF international registries [67–71] (Table 6). The age of patients (i.e., range 57.9–70.0 years) and female distribution (i.e., range 41.0–57.6%) were in the ranges reported in the registries of this review. The South Asian registries reported wider variabilities in the rate of heart failure, hypertension and diabetes, but not stroke, compared with those in the Middle Eastern ones. The rates of the aforementioned co-morbidities were similar to those in the international registries except for stroke in the RE-LY AF registry, which reported a higher rate in the Middle East. RHD was the highest in India (31.5%) [67]. Similarly, there was a wide range in the rates of AF types in the South Asian registries of this study. The rates of paroxysmal and permanent AF were higher in the international registries. It is important to mention that the regions and distribution of countries in the international registries were different from the WHO regions which were used in our study. The RE-LY AF registry [67] concluded with large regional variations in age, co-morbidities, risk factors, and management. Finally, substantial regional differences in stroke prevention have been found in the GLORIA-AF registry during its phase II, with an oral anticoagulation use rate of 87.4% in Africa/Middle East [63], which was higher than the rate reported in this review (i.e., range 38.5–51.9%).

6. Literature gaps and future directions

Our review identified several gaps in AF literature related to Middle Eastern Arabs and South Asians. Importantly, most of the available evidence was based on studies in the hospital setting with a paucity of informative community-based or population-based studies representative of these two ethnicities/races. This is particularly important in correctly identifying the AF disease prevalence and burden. Socio-economic difficulties are an important barrier for the conduct of these types of studies but can be overcome by joining internationally funded studies with samples of these and other ethnicities representative of the population. Furthermore, studies that address ethnic/racial in-equality and access to treatment, particularly oral anticoagulation, and the impact on outcomes, are lacking and should be boldly addressed in populations with mixed ethnicities and races including Middle Eastern Arabs and South Asians. In addition, how ethnicity and race affect AF presentation, symptomatology and interpretation needs to be examined. The Flow-AF registry is currently ongoing to recruit 1446 patients with a new non-valvular AF diagnosis across four Middle Eastern countries (Egypt, Lebanon, KSA, UAE). The registry will examine patients’ characteristics, patterns of treatment, clinical outcomes, and the economic aspects of treatment [72].

7. Limitations

Although our study was conducted using rigorous and systematic search strategy, it is possible that some articles were not identified by our search. The unidentified papers could contribute to a potential bias in the presented results with unknown impact. Moreover, the gap in the time between the literature search and completing results synthesis may have contributed to missing recently published relevant papers. However, we believe that this limitation may be balanced by the meticulousness of our methodology and the included literature.

8. Conclusions

Although in this scoping study we identified and summarized studies addressing clinical features and management of AF in Middle Eastern Arabs and South Asians, the main body of evidence comes from hospital-based studies. Thus, considered a limited and incomplete evidence. There is, additionally, an evidence gap of knowledge of AF burden that should be addressed in representative community or population-based studies. Our study highlights the need to further examine the effects of ethnicity and race in heart diseases particularly in AF.
Author contributions
Authors AS & RK—Conceptualization, literature search, study selection, data extraction, preparing figures/tables and manuscript writing. Authors AS and SA made substantial contributions to the conception or design of the work; analysis and interpretation of data for the work. Author VS critically revised the paper for important intellectual content and final editing of the version to be published. All authors read and approved the final manuscript.

Ethics approval and consent to participate
Not applicable.

Acknowledgment
Not applicable.

Funding
Open Access funding provided by the Qatar National Library.

Conflict of interest
The authors declare no conflict of interest.

Supplementary material
Supplementary material associated with this article can be found, in the online version, at https://rcm.imrpress.com/E N/10.31083/j.rcm2204127.

References
[1] Nanda A, Kabra R. Racial Differences in Atrial Fibrillation Epidemiology, Management, and Outcomes. Current Treatment Options in Cardiovascular Medicine. 2019; 21: 85.
[2] Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, et al. Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association. Circulation. 2021; 143: e254–e743.
[3] Staerk L, Sherer JA, Ko D, Benjamin EJ, Helm RH. Atrial Fibrillation: Epidemiology, Pathophysiology, and Clinical Outcomes. Circulation Research. 2017; 120: 1501–1517.
[4] Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Annals of Internal Medicine. 2018; 169: 467–473.
[5] Arksey H, O’Malley L. Scoping studies: towards a methodological framework. International Journal of Social Research Methodology. 2005; 8: 19–32.
[6] World Health Organization. WHO regional offices. Available at: https://www.who.int/about/who-we-are/regional-offices# (Accessed: 25 September 2020).
[7] Al-Turaiki AM, Al-Ammari MA, Al-Harbi SA, Khalidi NS, Alkatheri AM, Aldebsa TM, et al. Assessment and comparison of CHADS2, CHA2DS2-VASc, and has-BLED scores in patients with atrial fibrillation in Saudi Arabia. Annals of Thoracic Medicine. 2016; 11: 146–150.
[8] Anouassi Z, Atlallah B, Alsoud LO, Elnekidy W, Al Mahmood W, Aljaabari M, et al. Appropriateness of the Direct Oral Anticoagulants Dosing in the Middle East Gulf Region. Journal of Cardiovascular Pharmacology. 2021; 77: 182–188.
[9] Balaghi-Inalou M, Parsa SA, Gachkar L, Andalib S. Anticoagulant Therapy in Atrial Fibrillation for Stroke Prevention: Agreement of Agreement between Clinicians’ Decision and CHA2DS2-VASc and has-BLED Scores. High Blood Pressure & Cardiovascular Prevention. 2018; 25: 61–64.
[10] Ben Rejeb O, Brahim W, Ghali H, Erneez S, Mahdhaoui A, Jeridi G. Epidemiology of thromboembolic and hemorrhagic events in patients with atrial fibrillation under anti-vitamin K. Tunisie Medicale. 2019; 97: 432–437.
[11] Bin Salih SA, Showlag MS, Al-Qahtani MA, Taha A, Yousuf M, Abdullah M. Clinical characteristics of patients with atrial fibrillation at a tertiary care hospital in the central region of Saudi Arabia. Journal of Family & Community Medicine. 2011; 18: 80–84.
[12] Elkhatib THM, Elsaid AF, Al-Molla RM, Khamis MEM, Fahmi RM. Prevalence and Associated Risk Factors of Cerebral Microbleeds in Egyptian Patients with Acute Ischemic Stroke and Atrial Fibrillation. Journal of Stroke and Cerebrovascular Diseases. 2020; 29: 104703.
[13] Garadh T, Gabani S, Alawi MA, Abu-Taleb A. Prevalence and Predisposing Factors of Atrial Fibrillation in a Multi-Ethnic Society: the Impact of Racial Differences in Bahrain. Open Journal of Cardiovascular Surgery. 2011; 4: 9–16.
[14] Habibzadeh F, Yadollahie M, Roshanipoor M, Haghighi AB. Prevalence of atrial fibrillation in a primary health care centre in Fars Province, Islamic Republic of Iran. Eastern Mediterranean Health Journal. 2004; 10: 147–151.
[15] Khan ZA, Ahmad B, Hussain C, Hassan MU, Amin F, Iqbal A. Frequency of atrial fibrillation and its common clinical outcomes among patients presenting with acute myocardial infarction. Pakistan Heart Journal. 2014; 47: 123–126.
[16] Mashat AA, Subki AH, Balkhaider MA, Baabdullah WM, Walid JB, Alobadi AH, et al. Atrial fibrillation: risk factors and comorbidities in a tertiary center in Jeddah, Saudi Arabia. International Journal of General Medicine. 2019; 12: 71–77.
[17] Qanash SA, Kinsara AJ. Atrial fibrillation in Saudi patients. Annals of Saudi Medicine. 2011; 31: 318–319.
[18] Rehman Hu, Ahmed B, Hadi A, Ahmad I. Frequency and in hospital complications of atrial fibrillation in patients with acute ST segment elevation myocardial infarction. Medical Forum Monthly. 2017; 28: 7–11.
[19] Ritha M, Al-Sayed Amin A, Saleh SA, Cherial B, Al-Kandari F, Redha F, et al. The Prevalence of Atrial Fibrillation among Acute Medical Admissions in Kuwait. Medical Principles and Practice. 2005; 14: 136–139.
[20] Sadeghi R, Parsa Mahjoob M, Asadollahi M, Abbasi Z. Prevalence, main determinants, and early outcome of patients with atrial fibrillation hospitalized with ischemic stroke: evaluation of the value of risk assessment scores for predicting risk of stroke or major bleeding following anticoagulation therapy. Acta Bio-Medica: Atenei Parmensi. 2015; 86: 162–169.
[21] Shatoor AS, Ahmed ME, Said MA, Shabbir A, Ibrahim S, Jallad S, et al. Prevalence and associated factors of undiagnosed atrial fibrillation among end-stage renal disease patients on maintenance haemodialysis: a cross-sectional study. BMC Cardiovascular Disorders. 2020; 20: 186.
[22] AlAwwa I, Al-Hindi R, Alfraihat N, Obeid A, Ibrahim S, Jallad S, et al. Prevalence and associated factors of undiagnosed atrial fibrillation among end-stage renal disease patients on maintenance haemodialysis: a cross-sectional study. BMC Cardiovascular Disorders. 2020; 25: 101–105.
[23] Haq U, Lip GYH. A prospective survey of acute hospital admissions with atrial fibrillation in Karachi, Pakistan. Journal of the Royal College of Physicians of Edinburgh. 2009; 39: 200–203.
[24] Ullah I, Ahmad F, Ahmad S, Hayat Y. Atrial fibrillation and stroke prevention practices in patients with candidacy for anticoagulation therapy. Journal of Ayub Medical College, Abbottabad. 2015; 27: 669–672.
[25] Aljani M, Almazrooa L, Alhabib KF, Elasfar AA, Alfaileh H, Albaekr H, et al. Atrial Fibrillation in Patients Hospitalized with Heart Failure: Patient Characteristics and Outcomes from the HEARTS Registry. Angiology. 2018; 69: 151–157.
Hersi A, Alhabib KF, Alsheikh-Ali AA, Sulaiman K, Alfaleh HF, Alsaif S, et al. Prognostic Significance of Prevalent and Incident Atrial Fibrillation among Patients Hospitalized with Acute Coronary Syndrome: findings from the Gulf RACE-2 Registry. Angiology. 2012; 63: 466–471.

Imam YZ, Kamran S, Akhtar N, Deale D, Singh R, Malik RA, et al. Incidence, clinical features and outcomes of atrial fibrillation and stroke in Qatar. International Journal of Stroke. 2020; 15: 85–89.

Raghaoui Y, Chehbouni C, Hammiri AE, Habbal R. Epidemiology of the relationship between atrial fibrillation and heart failure. Pan African Medical Journal. 2017; 26: 116. (In French)

Salam AM, AlbaniHA, Al-Sulaiti EM, Al-Mulla AW, Singh R, Al Suwaidi J. Effect of age on treatment, trends and outcome of patients hospitalized with atrial fibrillation: insights from a 20-years registry in a Middle-Eastern country (1991–2010). Aging Clinical and Experimental Research. 2012; 24: 682–690.

Heidalari M, Bakhshandeh H, Fazellifar A, Haghjoo M. Clinical profile and outcome of familial versus non-familial atrial fibrillation. International Journal of Cardiology. 2020; 314: 70–74.

Hersi A, Abdul-Moneim M, Almoussad A, Al-Samadi F, Al-Fagih A, Sweiadan R. Saudi Atrial Fibrillation Survey: national, observational, cross-sectional survey evaluating atrial fibrillation management and the cardiovascular risk profile of patients with atrial fibrillation. Angiology. 2015; 66: 244–248.

Zubaid M, Rashed WA, Alsheikh-Ali AA, AlMahmeed W, Shehab A, Sulaiman K, et al. Gulf Survey of Atrial Fibrillation Events (Gulf SAFE). Circulation: Cardiovascular Quality and Outcomes. 2011; 4: 477–482.

Bhardwaj R. Atrial fibrillation in a tertiary care institute - a prospective study. Indian Heart Journal. 2012; 64: 476–478.

Dhungel S, Lautari S. Clinical Profile of Atrial Fibrillation in a Tertiary Hospital in Central Nepal. Journal of the Nepal Medical Association. 2017; 56: 335–340.

Srisilpa S, Korathanakhu P. Predictors of clinical outcome among Thai patients with atrial fibrillation-associated acute ischemic stroke. Journal of Stroke and Cerebrovascular Diseases. 2020; 29: 104856.

Apisayawat S, Tangcharoen T, Wirarapatpong T, Yamwong S, Wiboonpolprasert S, Sritara P. CHA2DS2-VASc scores predict mortality after hospitalization for atrial fibrillation. International Journal of Cardiology. 2015; 185: 293–296.

Krittayaphong R, Rangsirin R, Thinkhamrop B, Hurst C, Rattana-konlal S, Sripaiboonkij N, et al. Prevalence and associating factors of atrial fibrillation in patients with hypertension: a nation-wide study. BMC Cardiovascular Disorders. 2016; 16: 57.

Negi PC, Sondhi S, Rana V, Rathoure S, Kumar R, Kolte N, et al. Prevalence, risk determinants and consequences of atrial fibrillation in rheumatic heart disease: 6 years hospital based-Himachal Pradesh- Rheumatic Fever/Rheumatic Heart Disease (HRF-RHD) Registry. Indian Heart Journal. 2018; 70: S68–S73.

Charanharayali Gopalan B, Namboodiri N, Abdulkutty J, Lip GY, Koshy AR, Krishnan Nair V, et al. Kerala Atrial Fibrillation Registry: a prospective observational study on clinical characteristics, treatment pattern and outcome of atrial fibrillation in Kerala, India, cohort profile. BMJ Open. 2019; 9: e025901.

Krittayaphong R, Winikul A, Methavigul K, Wongvipaporn C, Wisaratapong T, et al. Risk profiles and pattern of antithrombotic use in patients with non-valvular atrial fibrillation in Thailand: a multicenter study. BMC Cardiovascular Disorders. 2018; 18: 174.

Narasimhan C, Verma JS, Ravi Kishore AG, Singh B, Dani S, Chawala K, et al. Cardiovascular risk profile and management of atrial fibrillation in India: Real world data from RealiseAF survey. Indian Heart Journal. 2016; 68: 663–670.

Sawhney JP, Kothiwale VA, Bisve N, Durgaprasad R, Jadhav P, Chopda M, et al. Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry. Indian Heart Journal. 2018; 70: 828–835.

Vora A, Kapoor A, Nair M, Lokhandwala Y, Narasimhan C, Ravikishore AG, et al. Clinical presentation, management, and outcomes in the Indian Heart Rhythm Society-Atrial Fibrillation (IHRSS-AF) registry. Indian Heart Journal. 2017; 69: 43–47.

Dabdooh WA, Bener A, Al-Mohannadi D, Numan MT, Albinali HA, Al-Suwaidi J. Epidemiology of atrial fibrillation among Qatari patients admitted with various cardiovascular disorder: a population-based study. Saudi Medical Journal. 2007; 28: 1457–1459.

Salam AM, Albinali HA, Al-Mulla AW, Asaad N, Singh R, Al-Qahtani A, et al. Women hospitalized with atrial fibrillation: gender differences, trends and outcome from a 20-year registry in a Middle Eastern country (1991–2010). International Journal of Cardiology. 2013; 168: 975–980.

Salam AM, Albinali HA, Al-Mulla AW, Singh R, Al Suwaidi J. Secular trends, treatments, and outcomes of Middle Eastern Arab and South Asian patients hospitalized with atrial fibrillation: insights from a 20-year registry in Qatar (1991–2010). Angiology. 2013; 64: 498–504.

Salam AM, Al BHA, Singh R, Gehani A, Asaad N, Al-Qahtani A, et al. Atrial fibrillation in Middle Eastern Arab and South Asian patients hospitalized with acute myocardial infarction: experience from a 20-year registry in qatar (1991–2010). Acta Cardiologica. 2013; 68: 173–180.

Salam AM, Albinali HA, Salim I, Singh R, Asaad N, Al-Qahtani A, et al. Impact of religious fasting on the burden of atrial fibrillation: a population-based study. International Journal of Cardiology. 2013; 168: 3042–3043.

Salam AM, Gersh BJ, Albinali HA, Singh R, Asaad N, Al-Qahtani A, et al. The prognostic implications of lack of palpitations in patients hospitalised with atrial fibrillation: observations from a 20-year registry. International Journal of Clinical Practice. 2014; 68: 122–129.

Salim I, Al Suwaidi J, Albinali HA, Singh R, Al-Qahtani A, Asaad N, et al. Impact of Chronic Kidney Disease on the Presentation and Outcome of Patients Hospitalized with Atrial Fibrillation: Insights from Qatar. Angiology. 2018; 69: 212–219.

Apostolakis S, Zubaid M, Rashed WA, Alsheikh-Ali AA, Almahmeed W, Shehab A, et al. Assessment of stroke risk in Middle Eastern patients with atrial fibrillation: the Gulf SAFE registry. International Journal of Cardiology. 2013; 168: 1644–1646.

Domek M, Li Y, Gumprecht J, Asaad N, Rashed W, Alsheikh-Ali A, et al. One-year all-cause mortality risk among atrial fibrillation patients in Middle East with and without diabetes: the Gulf SAFE registry. International Journal of Cardiology. 2020; 302: 47–52.

Domek M, Gumprecht J, Li Y, Proietti M, Rashed W, Al Qudaimi A, et al. Compliance of atrial fibrillation treatment with the ABC pathway in patients with concomitant diabetes mellitus in the Middle East based on the Gulf SAFE registry. European Journal of Clinical Investigation. 2021; 51: e13385.

Gumprecht J, Domek M, Proietti M, Li YG, Asaad N, Rashed W, et al. Compliance of Atrial Fibrillation Treatment with the Atrial Fibrillation Better Care (ABC) Pathway Improves the Clinical Outcomes in the Middle East Population: A Report from the Gulf Survey of Atrial Fibrillation Events (SAFE) Registry. Journal of Clinical Medicine. 2020; 9: 1286.

Li Y, Miyazawa K, Wolff À, Zubaid M, Alsheikh-Ali AA, Sulaiman K, et al. One-year risks of stroke and mortality in patients with atrial fibrillation from different clinical settings: the Gulf SAFE registry and Darlingon AF registry. International Journal of Cardiology. 2019; 274: 158–162.

Miyazawa K, Li Y, Rashed WA, Al Mahmeed W, Shehab A, Zubaid M, et al. Secondary stroke prevention and guideline adherent antithrombotic treatment in patients with atrial fibrillation: Insights from the Gulf Survey of atrial fibrillation events (Gulf SAFE). International Journal of Cardiology. 2019; 274: 126–131.

Shehab A, Zubaid M, Bhagavathula AS, Rashed WA, Alsheikh-Ali AA, Almahmeed W, et al. Sex differences in management and outcomes of patients with atrial fibrillation in the Middle East: Gulf

Volume 22, Number 4, 2021 1195
survey of atrial fibrillation events (Gulf SAFE). PLoS ONE. 2017; 12: e0175405.

[59] Zubaid M, Rashed WA, Alsheikh-Ali AA, Al-Zakwani I, AlMahmeed W, Shehab A, et al. Management and 1-year outcomes of patients with atrial fibrillation in the Middle East: Gulf survey of atrial fibrillation events. Angiology. 2015; 66: 464–471.

[60] Krittayaphong R, Winijkul A, Kunjara-Na-Ayudhya R, Apiyawsat S, Siriwatana K, Kanjanarutjawiwat W, et al. Adherence to Anticoagulant Guideline for Atrial Fibrillation Improves Outcomes in Asian Population: The COOL-AF Registry. Stroke. 2020; 51: 1772–1780.

[61] Krittayaphong R, Phrommintikul A, Ngamjanyaporn P, Siriwatana K, Kanjanarutjawiwat W, Chantarat T, et al. Rate of anti-coagulant use, and factors associated with not prescribing anticoagulant in older Thai adults with non-valvular atrial fibrillation: a multicenter registry. Journal of Geriatric Cardiology. 2019; 16: 242–250.

[62] Lip GY, Golding DJ, Nazir M, Beevers DG, Child DL, Fletcher RJ. A survey of atrial fibrillation in general practice: the West Birmingham Atrial Fibrillation Project. The British Journal of General Practice. 1997; 47: 285–289.

[63] Lip GY, Bawden L, Hodson R, Rutland E, Snatchfold J, Beevers DG. Atrial fibrillation amongst the Indo-Asian general practice population. the West Birmingham Atrial Fibrillation Project. International Journal of Cardiology. 1998; 65: 187–192.

[64] Lau C, Gbadebo TD, Connolly SJ, Van Gelder IC, Capucci A, Gold MR, et al. Ethnic differences in atrial fibrillation identified using implanted cardiac devices. Journal of Cardiovascular Electrophysiology. 2013; 24: 381–387.

[65] Rahman F, Kwan GF, Benjamin EJ. Global epidemiology of atrial fibrillation. Nature Reviews. Cardiology. 2015; 11: 639–654.

[66] Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham study. The New England Journal of Medicine. 1982; 306: 1018–1022.

[67] Oldgren J, Healey JS, Ezekowitz M, Commerford P, Avezum A, Pais P, et al. Variations in cause and management of atrial fibrillation in a prospective registry of 15,400 emergency department patients in 46 countries: the re-LY Atrial Fibrillation Registry. Circulation. 2014; 129: 1568–1576.

[68] Mazurek M, Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener H, et al. Regional Differences in Antithrombotic Treatment for Atrial Fibrillation: Insights from the GLORIA-AF Phase II Registry. Thrombosis and Haemostasis. 2017; 117: 2376–2388.

[69] Huisman MV, Ma CS, Diener H, Dubner SJ, Halperin JL, Rothman KJ, et al. Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anti-coagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort. Europace 2016; 18: 1308–1318.

[70] Bassand J, Apenteng PN, Atar D, Camm AJ, Cools F, Corbalan R, et al. GARFIELD-AF: a worldwide prospective registry of patients with atrial fibrillation at risk of stroke. Future Cardiology. 2021; 17: 19–38.

[71] Gamra H, Murin J, Chiang C, Naditch-Brûlé L, Brette S, Steg PG. Use of antithrombotics in atrial fibrillation in Africa, Europe, Asia and South America: insights from the International RealiSEAF Survey. Archives of Cardiovascular Diseases. 2014; 107: 77–87.

[72] Sobhy MA, Khoury M, Almahmeed WA, Sah J, Di Fusco M, Mardekian J, et al. The atrial FibrilLatIn real World management registry in the Middle East and Africa: design and rationale. Journal of Cardiovascular Medicine. 2020; 21: 704–710.

